Prolium’s $50M Series A raise; COUR Pharma touts liver drug follow-upnews2026-03-03T15:32:03+00:00March 3rd, 2026|Endpoints News|
Theravance ends R&D, lays off 50% of workers after Phase 3 failnews2026-03-03T15:00:39+00:00March 3rd, 2026|Endpoints News|
Boehringer Ingelheim tried to use a tempting, tough cancer target for liver disease. It didn’t worknews2026-03-03T14:32:05+00:00March 3rd, 2026|Endpoints News|
Corrected: Hims’ pharmacy partner won’t reintroduce GLP-1 pill pulled from marketnews2026-03-03T14:24:24+00:00March 3rd, 2026|Endpoints News|
ICER to CMS: Lower Takeda blockbuster’s price to Stelara’s levelnews2026-03-03T14:03:50+00:00March 3rd, 2026|Endpoints News|
CMS’ Chris Klomp on what it will take for AI to succeed in healthcarenews2026-03-03T14:00:45+00:00March 3rd, 2026|Endpoints News|
Esperion to buy Corstasis and its nasal spray for edema for $75M upfrontnews2026-03-03T11:56:39+00:00March 3rd, 2026|Endpoints News|
Two more members added to ACIP ahead of March meetingnews2026-03-02T20:35:20+00:00March 2nd, 2026|Endpoints News|
United Therapeutics to take pulmonary hypertension drug to FDA for approvalnews2026-03-02T16:24:51+00:00March 2nd, 2026|Endpoints News|
Aardvark’s stock plummets on study pause; BioNTech heads to Phase 3 with DualityBio ADCnews2026-03-02T16:14:18+00:00March 2nd, 2026|Endpoints News|
